We have previously shown that noncytotoxic doses of camptothecin (CPT), a topoisomerase I-specific antagonist, inhibit retrovirus replication in acutely and chronically infected cells. To evaluate the efficacy of CPT as an antiretroviral drug in vivo, we injected newborn BALB/c mice with Moloney murine leukemia virus and adult NFS mice with Friend spleen focus-forming virus. The Moloney murine leukemia virus-injected mice developed lymphoma, and the Friend spleen focus-forming virus-injected mice developed erythroleukemia. CPT, administrated together with the virus or 1 or 2 days after virus injection, prevented the onset of the disease in both cases. We showed that repeated CPT treatments increased the effectiveness of the drug when administrated 3 days after virus injection. This ability of CPT to inhibit retrovirus-induced disease in vivo without causing any apparent toxic side effects suggests its application as a legitimate remedy for the treatment of retroviral diseases.
The clinical importance of retroviruses which cause disease in humans (i.e., human immunodeficiency virus [HIV] and human T-cell leukemia virus) and animals (i.e., equine infectious anemia virus [EIAV] and Moloney murine leukemia virus [Mo-MuLV]) has led to intensive attempts to identify specific inhibitors. One basis for developing antiretroviral drugs is a deeper understanding of the viral life cycle and of the proteins and enzymes involved in its replication. We have shown previously that topoisomerase I (topo I) activity is associated with retroviral particles (HIV and EIAV) and that in the case of EIAV, this activity is present in the viral core (18) . The virus-associated topo I activity was inhibited by camptothecin (CPT), a known specific inhibitor of eukaryotic topo I (1, 6, 9, 13) . The association of topo I activity with the viral particles and the possibility that this enzyme is involved in the viral life cycle led us to examine the effect of CPT on retroviral infection. We demonstrated that noncytotoxic doses of CPT inhibited HIV replication in acute infection of H9 cells at a high efficacy (>90%) (16) . Moreover, we found that CPT inhibited the replication of EIAV in chronically infected Cf2Th cells. Continuous exposure of these cells to the drug for 52 days revealed 85 to 92% inhibition of virus production. No effect on the viability or growth rate of the cells was detected (17) .
CPT is a cytotoxic alkaloid, isolated from Camptotheca acuminata, which has strong antitumor activity against a wide range of experimental tumors (3, 4, 23) . In cytotoxic doses, CPT inhibits RNA and DNA synthesis and causes rapid and reversible fragmentation of DNA in mammalian cells (8, 11, 21, 23) . These pleiotropic effects were shown to be mediated via a single cellular target, topo I (reviewed in reference 13).
Our in vitro results indicate that CPT can act as an antiviral drug at noncytotoxic doses. However, an accurate portrayal of human diseases cannot rely exclusively on extrapolations from in vitro data. Therefore, experiments * Corresponding author.
with animal models are essential for evaluating the efficacy of a specific drug in vivo. We examined the effect of CPT as an antiretroviral drug in mouse models using two different retroviruses Mo-MuLV and Friend spleen focus forming virus (SFFV). Mo-MuLV is a type C retrovirus which cause leukemia in adult mice after a long latency period (reviewed in reference 24). Newborn mice that are given injections of the virus develop lymphoma 2 to 3 months after viral injection (12) . Friend murine leukemia retrovirus complex is composed of a replication-competent Friend murine leukemia helper virus and an acutely transforming, replicationdefective spleen focus-forming virus (2, 10, 22) . Friend murine leukemia retrovirus complex caused rapid development of erythroleukemia associated with severe immunosuppression when inoculated into newborn or adult mice of susceptible strains. The mice inoculated with SFFV developed the disease 3 to 4 weeks after injection and died after 6 to 7 weeks, thus enabling us to determine the effect of CPT in vivo in a relatively short time.
Effect of CPT on Mo-MuLV replication in acutely infected NIH 3T3 cells. Before analyzing the effect of CPT on in vivo Mo-MuLV infection, we determined its effect on this virus under in vitro conditions. For this purpose, NIH 3T3 cells were infected with MOV3(neo) (a mixture of MOV3, which is a clone of Mo-MuLV [7] , and Mo-MuLV bearing the neomycin resistance [Neorj gene) (7) . Cells (105 per plate) treated with Polybrene (8 ,ug/ml) were infected with 5 x 106 PFU of the virus in the presence of various CPT concentrations (0.002 to 2 ,uM) for 1 h. We found that treatment of the cells with 0.002 to 0.2 ,uM CPT was not toxic to the cells (data not shown).
Virus-infected cells were selected by growing the cells in the presence of G418 (400 ,ug/ml), and the number of neomycin-resistant foci was determined. Noncytotoxic CPT doses were found to inhibit Neor focus formation by 40 to 88% (Table 1 ). To further substantiate the effect of CPT on viral replication, we used the infectious-center technique. Using this method, we could determine the number of virus-producing cells obtained after CPT treatment. For this purpose, NIH 3T3 cells were infected with MOV3 in the presence of various CPT doses. Twenty-four hours after infection, the cells were suspended by trypsinization, and 100 ,ul of serial dilutions of each suspension was applied onto plates containing subconfluent cultures of FG10 cells (which contain a replication-defective Moloney murine sarcoma virus). The virus produced by the NIH 3T3 cells can infect the FG10 cells, and transformed foci will be obtained. The number of the transformed foci obtained is directly correlated with the number of NIH 3T3 cells which produce virus.
As can be seen in Table 2 , noncytotoxic doses of CPT inhibited the formation of infectious centers by 60 to 85%. Effect of CPT on Mo-MuLV-induced disease in newborn mice. To evaluate the in vivo effect of CPT, we analyzed its influence on the development of the disease caused by Mo-MuLV in mice. Newborn BALB/c mice were inoculated with 3 x 105 PFU (19) of Mo-MuLV 24 to 72 h after birth. These mice developed splenomegaly 10 weeks after viral injection. Although it has been claimed that this virus may induce thymic lymphoma (12) , in our studies no significant changes in the appearance of the thymus in our BALB/c mice were observed. Figure 1 demonstrates that the average weight of spleens of Mo-MuLV-inoculated mice was 500 + 220 mg, while injection of the virus together with CPT (1 mg/kg of body weight) revealed an average spleen weight of 188 ± 60 mg. The average spleen weight of the uninfected control mice was 100 ± 10 mg. Mice inoculated with 1 mg of CPT alone per kg did not show any effect on the spleen size or any visible side effects. Histopathological analysis clearly showed that the spleens from Mo-MuLV-inoculated mice were heavily populated with lymphoma cells, while the spleens from CPT-treated mice showed the normal spleen cell population (compare Fig. 2A through D) .
We wanted to see whether repeated CPT treatment would improve the efficacy of the drug. As can be seen in Fig. 3 , injection of CPT every 5 days abolished splenomegaly completely. The average spleen weight of mice receiving three drug injections was 150 ± 10 mg. In order to evaluate the efficacy of CPT administered after virus injection, newborn BALB/c mice were given an injection of Mo-MuLV, and CPT was administrated in a single dose 1, 2, or 3 days after virus injection. Figure 4 indicates that CPT administration 1 or 2 days after virus injection prevents or significantly reduces development of splenomegaly, while injection of CPT 3 days after virus injection reduced spleen enlargement by 25%. Since a single CPT dose given 3 days after virus infection was insufficient to reduce splenomegaly, we treated the mice with additional CPT doses 9 and 15 days after virus injection. As can be seen in Fig. 4 inoculated, non-CPT-treated mice was 513 + 150 mg, while mice given injections of cells from CPT-treated mice had an average spleen weight of 150 + 20 mg. These results indicate that CPT-treated spleens did not contain transformed cells; this substantiates our hypothesis that CPT inhibits the onset of lymphoma caused by Mo-MuLV and may act as an antiretroviral drug with high efficacy.
Inhibition of Friend virus-induced disease in mice by CPT. In order to determine the effectiveness of CPT treatment on retrovirus-induced disease in adult mice, the Friend virus-SFFV-infected mouse model was used. A well-characterized stock of SFFV in complex with an amphotropic Friend murine type C virus, which induces only a low incidence of lymphoid and myeloid disease after a long latency (0.1 ml; 105 PFU), was injected intraperitoneally into adult NFS mice. NFS mice were inoculated intraperitoneally in the presence of CPT (5 mg/kg) or 1% dimethyl sulfoxide (DMSO) (CPT was solubilized in DMSO; thus, the same DMSO concentration was injected into the virus-inoculated mice). To determine the efficacy of CPT administrated after
SFFV inoculation, mice were inoculated intraperitoneally with 5 mg of CPT per kg 3 days after virus infection. Figure  5 demonstrates that CPT administrated concomitantly with the virus prevented the onset of splenomegaly.
Moreover, injection of the drug 3 days after virus inoculation was still very effective. The CPT dose used did not produce any visible toxic effect. In conclusion, it is of interest to note that while our previous studies have demonstrated that CPT inhibits the replication of two lentiviruses, HIV and EIAV (16, 17) , the present experiments show a similar effect of this drug with type C retroviruses, indicating that CPT is a general antiretroviral agent. We demonstrated in this study that CPT could efficiently prevent the pathogenicity of two different retroviruses, Mo-MuLV and SFFV, in mice at nontoxic doses. Single doses of the drug given together with the virus or 1 or 2 days after virus infection completely prevented induction of splenomegaly by either of these viruses. It should be noted that we kept virus-inoculated and CPT-treated mice for 15 months and did not observe any splenomegaly, indicating that CPT prevents the onset of the disease rather than just delaying it. However, our results indicated that this drug is very effective during the early stages of virus infection. One of the main problems of in vivo drug administration is the possible toxic side effects caused by the drug. As an anticancer drug, CPT had severe toxic effect when it was given in cytotoxic doses (5, 14, 15, 20) . However, the CPT doses which we used in our experiments did not cause any visible toxic effects. On the basis of our in vitro studies, it is reasonable to attribute the inhibitory effect of the drug on the onset of retrovirusinduced diseases to its antiretroviral activity, although we cannot exclude the possibility that the dramatic effect of this drug on the onset of the disease is due to some effect on the cellular targets of the virus in the mice. However, our data 5 . Effect of CPT treatment on NFS mice infected with SFFV. NFS mice (6 to 8 weeks old) were inoculated intraperitoneally with 0.1 ml of medium containing 105 PFU of SFFV. Mice were treated with CPT (5 mg/kg) which was injected together with the virus or 3 days after virus infection. Control uninfected mice were given an injection of medium containing 1% DMSO or 5 mg of CPT per kg. Five weeks after virus injection, the mice were sacrificed, and their spleens were weighed. Each bar represents the mean spleen weight + standard deviation for 6 to 10 mice. Symbols: _, DMSO control; E1, CPT control; M, SFFV alone; Ci, SFFV and CPT together; Mi, CPT 3 days after SFFV infection.
